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Available online 8 December 2011Abstract Stromal fibroblasts are a new prospective drug target. Mesenchymal stromal cells (MSCs) and monocyte-derived
stromal cells, also known as fibrocytes, are distinct fibroblastic populations derived from separate lineages. Mesenchymal
and myeloid fibroblast progenitors are multipotent, serve as progenitor cells in animal models, and are implicated in several
diseases. In addition, epithelial-mesenchymal transition (EMT) has been established as a mechanism for generation of stromal
cells. Organ sources, relative contributions, and functions of these populations in normal development and pathology are not
well understood. Innovative approaches are needed to identify markers that can distinguish these stromal populations.
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Stromal cells, typically identified as tissue-resident fibro-
blasts, form a supportive scaffold for both healthy and patho-
logical tissues. Stromal cells implicated in disease can be
divided into three broad types: mesenchymal stromal cells
(MSCs), monocyte-derived stromal cells and stromal cells aris-
ing through epithelial-mesenchymal transition (EMT). Our
unpublished data (Fig. 1) show the appearance of cells derived
from these three alternative lineages in ex vivo culture. These
cell populations are important players in development and tis-
sue remodeling, regeneration of damaged organs, and fibrosis
because they secrete growth/immunomodulatory factors and
extracellular matrix (ECM) components. There are three key
questions about stromal cells. First, due to the lack of specific
markers, we do not know the relative contributions of MSCs,
fibrocytes and EMT-derived cells to stroma in healthy and
pathological organs. Second, much remains to be understood
about whether these fibroblastic populations execute syner-
gistic or antagonistic functions in disease. Third, it is unclear
to what extant systemic mobilization and recruitment of pro-
genitors from the bone marrow as opposed to their migration
from extramedullary organs or resident tissues contributes to
the formation of stroma.
Mesenchymal stromal cells
Mesenchymal stromal cells (MSCs) exist in many adult organs
(da Silva Meirelles et al., 2006) and have a typical fibroblast
appearance in culture (Fig. 1A). MSCs can be distinguished
from hematopoietic cells based on the lack of the pan-Figure 1 Morphology of human stromal populations in cell culture
blood of a prostate cancer patient as described (Bellows et al., 201
peripheral blood of a control cancer-free donor as described (Bellow
retroviral-mediated expression of SV40 Large and Small T antigens a
EMT through ectopic expression of Snail using the pBabe retroviral ve
on uncoated plastic in αMEM medium containing 10% fetal calf serumleukocyte marker CD45 and distinguished from endothelial
cells based on the lack of the pan-endothelial marker
CD31/PECAM-1 (Bianco et al., 2008; Rodeheffer et al.,
2008). A number of cell surface molecules, including
platelet-derived growth factor receptor (PDGFR), Stro-1,
CD13, CD29, CD44, CD73, CD90, CD105, and CD146, have
been used for positive selection of MSCs (Gimble et al.,
2007; Bianco et al., 2008). MSCs were first isolated from
bone marrow stroma and termed fibroblast colony-forming
units (CFU-F) based on their morphology (Friedenstein,
1980). The ability of MSCs to differentiate into cells of meso-
dermal lineages, such as osteoblasts, chondrocytes, and ad-
ipocytes, has resulted in the term “mesenchymal stem cells”
(Prockop, 1997; Caplan, 2007). In addition to their mesen-
chymal progenitor function, MSCs serve as pericytes (mural
cells) maintaining vascular integrity in homeostatic condi-
tions (Crisan et al., 2008; Tang et al., 2008; Traktuev et
al., 2008).
Differentiation of mesenchymal progenitors into fibro-
blasts is proposed to be a major source of stromal cells in
both normal development and pathology (Bianco et al.,
2008). MSCs are the primary source of collagen I in the
ECM, deposition of which is an integral component of
wound healing as well as fibrosis (Wynn, 2008). Preclinical
studies and clinical trials with allografted MSCs indicate
the intrinsic therapeutic potential of these cells and suggest
that they are activated in disease to engage in tissue repair
and regeneration (Toma et al., 2009; Caplan and Correa,
2011). This support involves angiogenic activity and the
immunoprotection provided by the MSCs. The trophic activi-
ty of MSCs results from a number of bioactive molecules that
they secrete to suppress apoptosis and scarring and to. (A) Primary MSC (passage 0) isolated as CFU-F from peripheral
1a). (B) Primary adherent monocytes (passage 0) isolated from
s et al., 2011a). (C) Mammary epithelial cells immortalized by
nd the catalytic subunit of telomerase and induced to undergo
ctor as described (Mani et al., 2008). Cells in A–C were cultured
. Scale bar: 50 μM.
314 M.G. Kolonin et al.promote cell proliferation and vascularization. In addition,
MSCs have immuno-modulatory properties (Jones and
McTaggart, 2008), and their capacity to mute T-cell benefit
autoimmune disease patients and favors the outcome of
bone marrow transplantation through the suppression of
graft-versus-host-disease.
MSCs are virtually absent in the peripheral circulation of
healthy individuals, however, hypoxia and inflammation sig-
nals have been reported to result in MSC mobilization and
migration from their niches (Rochefort et al., 2006;
Okumura et al., 2009). Interestingly, systemic circulation
of MSCs is observed in obesity (Bellows et al., 2011b) and is
further elevated in cancer (Bellows et al., 2011a). This find-
ing is reinforced by reports on mobilization of mesenchymal
perivascular progenitors in cancer (Mancuso et al., 2011) as
well as in acute stroke patients (Jung et al., 2011). Future
studies will be needed to address bloodstream, as opposed
to migration through solid tissues, as alternative routes of
MSC trafficking to pathological sites.Hematopoietic-derived stromal cells
Not only mesenchymal, but also hematopoietic cells are
recruited as components of stroma (Coussens and Werb,
2002). Leukocytes can display matrix adherence and plastic-
ity in culture (Fig. 1B). When cultured for 2 weeks in the
presence of heat-treated serum, or cultured for 4–5 days in
the absence of serum, a small percentage of peripheral
blood leukocytes differentiate into spindle-shaped cells
called fibrocytes that express both hematopoietic markers
and stromal markers such as collagen-I (Bucala et al., 1994;
Chesney et al., 1997; Pilling et al., 2009). It is believed
that fibrocytes originate from a subset of bone marrow-
derived monocytes (Bucala et al., 1994; Abe et al., 2001).
In this review, all hematopoietic origin fibroblast-like cells
will be referred to as fibrocytes, although it is currently
not clear whether they are all derived from the same leuko-
cyte subtype through the same mechanism in vivo. Fibro-
cytes express the pan-hematopoietic cell marker CD45
along with CD11b and several other monocyte markers (Abe
et al., 2001). On the other hand, in culture these cells can
be induced to express markers typically used for MSC identi-
fication, such as CD13, and CD29 along with CD34, as well as
collagen I and other ECM proteins (Chesney et al., 1998;
Pilling et al., 2007).
Although there is no single marker that can be used to
identify fibrocytes, staining cells or tissues for combinations
of markers can be used to distinguish human fibrocytes from
certain differentiated monocytic populations and from mes-
enchymal fibroblasts (Pilling et al., 2009). An intriguing ob-
servation is that collagen I-positive cells can be found in
the circulation, although it is currently unknown whether
these are cells that are about to enter a tissue and become
a tissue fibrocyte, or whether they are cells that had been
a tissue fibrocyte and have left the stroma and entered the
circulation (Mehrad et al., 2007; Reilkoff et al., 2011). It
has been proposed that fibrocytes can differentiate into
myofibroblasts, an event corresponding to the phenotypic
cell transition clinically observed in cancer and other fibrot-
ic pathologies (Mattoli et al., 2009; Strieter et al., 2009).
Fibrocytes are capable of substantially contributing tostroma in solid tissues (Hartlapp et al., 2001; Bellini and
Mattoli, 2007; Herzog and Bucala, 2010). Indeed approxi-
mately 50% of fibroblastic cells in non-malignant fibrotic le-
sions are bone marrow-derived and express CD45 (Ishii et al.,
2005), and in tumors stroma is also composed of both CD45+
and CD45− cells (Worthley et al., 2009).
Like MSCs, in addition to enforcing a fibrotic state in patho-
logical tissues, fibrocytes can promote angiogeneisis (Hartlapp
et al., 2001; Hong et al., 2005). While there are numerous sim-
ilarities between these two types of stromal progenitors, there
are also striking differences that are worth emphasizing. While
MSCs do not express MHC type-II, are immunoprivileged, and
suppress cytotoxic T-lymphocytes, fibrocytes express MHC-II
and activate T-cells (Chesney et al., 1997; Abe et al., 2001).
Thus, while possibly having similar ECM-producing and proan-
giogenic activities, MSCs and fibrocytes may have opposite ef-
fects on the immune response. Interestingly, fibrocytes, like
MSCs, can differentiate into specialized mesenchymal cells,
such as adipocytes (Hong et al., 2005; Ishii et al., 2005). More-
over, recent studies indicate that monocytic bone marrow-
derived cells can provide a substantial contribution to the
pool of adipocytes composing white adipose tissue (WAT) in
normal development (Crossno et al., 2006; Majka et al.,
2010), although these results have been disputed (Koh et al.,
2007; Tomiyama et al., 2008).EMT-derived stromal cells
The epithelial-to-mesenchymal transition is a series of cellular
remodeling events that facilitates a number of normal biologi-
cal processes, such as gastrulation and wound healing, as well
as several pathological processes, such as fibrosis and cancer
metastasis (Yang and Weinberg, 2008; Thiery et al., 2009). At
the most fundamental level, EMT is defined as the process
through which epithelial cells lose their epithelial traits and
gain characteristics associated with mesenchymal cells (Hay,
1995). Epithelial cells, which form the lining of glandular or-
gans, normally exist as sheets of cells tightly bound to one an-
other and to the basement membrane. However, during EMT,
epithelial cells dissociate these cell-to-cell and cell-to-
basementmembrane contacts in order tomigrate independent-
ly and invade through the extracellular matrix. As illustrated in
Fig. 1C, through the loss of these adhesions and extensive cyto-
skeleton remodeling, the epithelial cells also lose their typical
apical–basolateral polarity and take on a spindle-shaped mor-
phology (Shook and Keller, 2003; Yang and Weinberg, 2008;
Thiery et al., 2009). At the molecular level, EMT is associated
with decreased expression of epithelial adhesion molecules,
such as E-cadherin and epithelial cytokeratins. This loss of epi-
thelial gene expression is accompanied by de novo expression of
mesenchymal markers, such as vimentin, fibronectin, and N-
cadherin (Shook and Keller, 2003; Thiery and Sleeman, 2006).
EMT events were originally described during embryonic de-
velopment. During gastrulation, some of the cells located at
the primitive streak undergo EMT prior to ingression, and
these EMT-derived cells eventually form the embryonic endo-
dermal and mesodermal tissues (Bellairs, 1986). In fact, EMT
events are essential for embryonic development. If the ability
of embryonic cells to undergo EMT is impaired, embryonic de-
velopment ceases at the blastula stage (Thiery and Sleeman,
2006). Following gastrulation, EMT events occur during the
315Stroma cell progenitorsdevelopment of neural crest cells from the neural tube, cardiac
valve formation, palatal fusion, Müllerian duct regression, and
peripheral nervous system formation (Hay, 1995; Shook and
Keller, 2003; Yang et al., 2008). In addition, EMT may facilitate
natural remodeling events in some epithelial organs, such as
the branching morphogenesis of the mammary gland (Fata et
al., 2004).
Induction of EMT in immortalized human mammary epithe-
lial cells not only imparts fibroblast-like qualities (e.g. migra-
tory and invasive capabilities) to these cells, but also endows
them with traits similar to mammary stem cells (Mani et al.,
2008). Moreover, induction of EMT in immortalized human
mammary epithelial cells by exposure to a range of EMT-
inducing stimuli, including ectopic expression of the transcrip-
tion factors Twist or Snail, or treatment with TGF-beta, leads
to an increased ability to self-renew in mammosphere culture
and acquisition of the CD44high/CD24low “cancer stem cell”
profile (Al-Hajj et al., 2003; Mani et al., 2008; Morel et al.,
2008). Mammary stem cells isolated from normal mouse or
humanmammary glands, or from human breast cancer tissues,
express high levels of mesenchymal markers and EMT-inducing
transcription factors (Mani et al., 2008; Lim et al., 2010),
which is consistent with the notion that the EMT phenotype
is linked with stem cell properties.
Interestingly, both MSCs and EMT-derived epithelial cells
(Fig. 1C) exhibit mesenchymal traits (e.g. independent migra-
tion, invasiveness) and stem cell properties. EMT-derived
mammary epithelial cells and bone marrow-derived MSCs
share similar antigenic profiles and express relatively similar
levels of the mRNAs encoding several EMT-inducing transcrip-
tion factors (Battula et al., 2010). Similar to MSCs, EMT-
induced epithelial cells can differentiate into multiple meso-
dermal lineages, including osteoblasts, adipocytes, and chon-
drocytes, and home to wounded tissues upon intravenous
injection into mice (Battula et al., 2010).
In addition to epithelium, other tissues have also been
shown to undergo mesenchymal transdifferentiation. Most no-
table are the reports on the conversion of vascular cells into
multipotent mesenchymal progenitors (Medici et al., 2010).
This phenomenon of endothelial-to-mesenchymal transition
takes place in both malignant and non-malignant settings
(Zeisberg et al., 2007). Interestingly, MSCs can induce EMT in
adjacent malignant epithelial cells in tumors (Klopp et al.,
2010). Together, these observations suggest parallel biological
roles for MSCs and endogenous organ cells induced to undergo
mesenchymal transition during wound healing, fibrosis, and
other pathologies and calls for further analysis of the diversity
of MSC-like cells in these processes.Organ origins of stromal cell progenitors
Since the original work on macrophages pioneered by Metchni-
kov (Rossiianov, 2008), it has been considered that cells can
be recruited to pathological sites both from the surrounding
solid tissues and from remote organs through the circulatory sys-
tem (Fig. 2). While extravasation of various circulating leuko-
cytic populations is a well-characterized process, invasion of
cells from local niches through the ECM is a phenomenon that
is so far not well documented due to the lack of tools and cell
tracking markers (Coussens and Werb, 2002). In addition, it is
becoming apparent that the numbers and types of circulatingcells are dynamic and can change in disease. This can result in
a rapid increase in accessibility of cells that could become
attracted by pathological tissues. Mobilization of stem cells
and their descendent progenitor cells from the endogenous
pools residing in the bone marrow as well as extramedullary or-
gans may have clinical importance (Pelus, 2008; Kolonin and
Simmons, 2009). The notion that endogenous stem cells may
be activated to mend damaged tissues during injury repair and
organ regeneration has prompted efforts to identify factors mo-
bilizing stem cells.
Experiments aimed to distinguish bone marrow from
extramedullary pools of progenitors demonstrate that med-
ullary cells expressing myofibroblast markers such as α-
smooth muscle actin (αSMA) contribute to tumor stroma
(Quante et al., 2011). Moreover, there is evidence that
bone marrow MSCs can contribute to epithelial parenchyma
in pathology (Okumura et al., 2009). These findings confirm
other studies based on bone marrow transplantation in
mouse models showing that medullary MSCs could give rise
to tumor fibroblasts (Direkze et al., 2004; Udagawa et al.,
2006; Worthley et al., 2009). Conflicting with these reports
is experimental evidence that cells of mesenchymal stroma
do not transplant along with the marrow hematopoietic pro-
genitors (Simmons et al., 1987). This controversy could be
explained by the induced expression of myofibroblast and
mesenchymal markers in non-mesenchymal cells in the
tumor microenvironment. Such conversion can reportedly
take place not only through EMT, but also through
endothelial-to-mesenchymal transition (Zeisberg et al.,
2007). Identification of possibly existing organ-specific MSC
promoters would be necessary for lineage tracing experi-
ments that could resolve the ongoing debate.
The route through which fibroblast progenitors are
recruited to pathological organs is unclear. While monocytes,
which can become fibrocytes, are abundant in the peripheral
blood, circulating MSC progenitors are virtually absent in the
blood of healthy individuals (Kuznetsov et al., 2007). A body
of evidence indicates that hypoxia and inflammation signals
can cause MSC mobilization and migration from their niches
(Rochefort et al., 2006). MSCs appear to “sense” wounds and
malignant lesions, which explains their homing to the corre-
sponding sites (Spaeth et al., 2009). Transplantation experi-
ments have shown that the bone marrow serves a source of
progenitor cells that can traffic to pathological sites (Peters
et al., 2005; Papayannopoulou and Scadden, 2008). While
bonemarrow is generally accepted as a source of hematopoiet-
ic stem cells, marrow-derived pericytes and stromal cells have
been also reported in a number of studies (Bababeygy et al.,
2008). However, there also is evidence accumulating that
pools of mesenchymal progenitors are autonomously main-
tained in extramedullary organs (Koh et al., 2007; Tomiyama
et al., 2008). Thus, organs other than bone marrow may con-
tribute to the pool of mesenchymal stromal progenitors mobi-
lized in pathology and implicated in disease progression
(Kolonin and Simmons, 2009).Adipose tissue as a potential source of stromal cell
progenitors
In addition to adipocytes and vascular endothelial cells (EC),
WAT contains abundant perivascular MSCs termed adipose
Bone marrow Adipose tissue
MSC,
Fibrocytes
MSC,
Fibrocytes
Resident
tissue
Fibrosis / Cancer
MSC,
Fibrocytes
EMT
Figure 2 A model of pathological stroma. Mesenchymal stromal cells (MSCs) or fibrocytes from resident tissue, bone marrow, or adi-
pose tissue can be recruited into the site of disease along with epithelial-mesenchymal or endothelial-mesenchymal transition (EMT) in
the organ undergoing pathological remodeling. Parenchymal tissue transformation (light blue to dark blue) in cancer/fibrosis is accom-
panied by functional changes in the pathological stromal cells (gray to red). Red lines: matrix accumulation in fibrosis/cancer desmopla-
sia. Green: vasculature. Yellow: adipocytes.
316 M.G. Kolonin et al.stromal cells (ASCs), as well as infiltrating leukocytes
(Hausman et al., 2001; Daquinag et al., 2011b). ASCs comprise
a large proportion of the stromal/vascular fraction of WAT,
and display multipotency and proliferation capacities compa-
rable to those of bone marrow MSCs, while also having unique
features (Gimble et al., 2007; Noel et al., 2008). ASCs are a
heterogeneous population of cells lacking hematopoietic and
endothelial markers, at least some of which express CD34
(Traktuev et al., 2008; Zimmerlin et al., 2010). The relevance
of CD34 expression on ASCs, which is rapidly suppressed in cul-
ture, is unclear but may have functional relevance (Suga et
al., 2009). Both pericytes (Rodeheffer et al., 2008; Tang et
al., 2008; Traktuev et al., 2008) and tunica adventitia cells
(Corselli et al., in press) have been identified as ASCs with
the CD45–CD31–CD34+ immunophenotype.
ASCs promote endothelial cell proliferation and blood ves-
sel formation at least in part via trophic effects of secreted
vascular endothelial growth factor (VEGF), hepatocyte growth
factor (HGF), and other angiogenicmolecules (Traktuev et al.,
2008). Systemically administered ASCs localize to sites of inju-
ry and contribute to revascularization of injured mouse or-
gans, including the heart (Cai et al., 2009). On the other
hand, monocytes/macrophages infiltrate WAT in obesity and
significantly contribute to its cell content. The inherent ca-
pacity of monocytes/macrophages to migrate raises the possi-
bility that WAT-resident monocytes may have overlooked
pathological roles. Because monocytes are highly plastic and
can efficiently acquire fibroblast functions in culture and in
vivo (Abe et al., 2001; Hartlapp et al., 2001; Pilling et al.,
2003; Pilling et al., 2007), both mesenchymal and hematopoi-
etic cells from WAT are potential sources of pathological stro-
mal progenitors. Interestingly, CD34+CD45+ fibrocytes havebeen observed in WAT (Traktuev et al., 2008) but have not
been systematically characterized.
Obesity, hallmarked by overgrowth of WAT, is associated
with various fibrotic conditions, and WAT may represent a po-
tential source of progenitor cells mobilizable in disease
(Kolonin and Simmons, 2009). In obese individuals, there is in-
creased circulation of CD34-positive MSCs (Bellows et al.,
2011b). Our studies suggest that MSCs and fibrocytes from the
bone marrow as well as WAT might be mobilized in response
to pathological signals (Fig. 2). These cells might serve as a re-
serve of pathological stroma progenitors in obese patients upon
recruitment into the lesion. Excess WAT-derived progenitors
released into the bloodstream in obesity could positively influ-
ence post-operative healing and organ regeneration, and could
explain the “obesity paradox” of better post-surgical recovery
observed for obese patients (Mullen et al., 2009). The flip
side of excessive stromal cell mobilization may be that WAT-
derived cells overabundant due to WAT expansion become
recruited by tumors at an increased frequency in obese individ-
uals. This phenomenon may at least partially account for the
epidemiological association between obesity and disease pro-
gression reported for several types of cancer (Flegal et al.,
2007; Kant and Hull, 2011). We have proposed that infiltration
of WAT-derived cells into tumors results in higher concentra-
tions of adipokines that affect cancer cells in a paracrine fash-
ion, and could therefore be more potent than the endocrine
signaling from remote WAT depots (Zhang et al., 2010). The
possibility of ASCs, as well as of monocyte-derived cells from
WAT, shaping the tumor microenvironment is consistent with
recent reports on tumor stroma changes resulting from in-
creased adiposity (Zyromski et al., 2009; Park et al., 2010;
Dirat et al., 2011; Zimmerlin et al., 2011).
317Stroma cell progenitorsStromal cells in normal physiology
Stromatogenesis is an integral component of development.
In adulthood, every organ also relies on migration and prolif-
eration of stromal cells that generate the ECM, proper com-
position of which is essential for normal tissue homeostasis
and physiology. MSCs, hematopoietic progenitors, as well
as EMT-derived cells, participate in this process. Postneona-
tally, stromal cells maintain organ architecture. While their
turnover in healthy organs has not been systematically
assessed, they certainly undergo self-renewal (Jackson et
al., 2002). The current dogma is that MSCs are the primary
pool of cells serving as progenitors for connective tissues,
and transplantation experiments have demonstrated the
organogenic potential of MSCs (Bianco et al., 2008). Stromal
cell content in certain tissues is supported by the import of
progenitors from other organs. For example, according to re-
cent reports adipocytes can originate from bone marrow
monocytes (Crossno et al., 2006; Sera et al., 2009; Majka
et al., 2010), indicating mesenchymal transition as a con-
tributor to homeostatic stroma maintenance.
Wound healing is a specific setting in adulthood in which
stromal progenitors play an important role. Bone marrow
transplantation studies demonstrate that organ repair is
assisted by hematopoietic progenitors, at least indirectly,
through transient recruitment of blood cells sealing the
wound and priming the response against infection. Fibro-
cytes recruited from the blood are incorporated into the
scar tissue and become a component of the repaired organ
at least for a period of time. Non-bone marrow-derived cir-
culating progenitor cells also contribute to wound repair;
however the organ sources remain unknown (Aicher et al.,
2007). While tracking cell infiltration from the surrounding
solid organs is more challenging technically, it is believed
that not only hematopoietic descendents but also MSCs be-
come a structural and functional component of the repaired
tissue (Caplan and Correa, 2011). The long-term roles of
fibrocytes, MSCs, and EMT-derived cells in the maintenance
and resolution of scar tissue are unclear.Stromal cells in fibrosis
Progression of a number of pathologies resulting from genet-
ic predisposition, injury/infection and chronically affecting
respiratory, cardiovascular or digestive systems are associat-
ed with fibrotic tissue remodeling. Fibrosis is driven by acti-
vated stromal fibroblasts that deposit ECM proteins and
become similar to myofibroblasts in that they start expres-
sing αSMA (Neilson, 2006). Stromal progenitors are key
players in chronic tissue scarring. Previous studies in fibrosis
models demonstrated that fibrocytes, MSCs, and EMT-
derived cells co-exist in non-malignant pathology; however
their contributions and roles are not defined at present.
The notion that EMT plays an important role in the formation
of fibrotic scar tissue is widely accepted; however solid evi-
dence is still lacking (Kriz et al., 2011). Because fibrocytes
and MSCs also secrete collagen I and other ECM molecules,
each one of them has the capacity to contribute to scar for-
mation (Fig. 3). It could be expected that fibrocytes, which
promote the immune response, support the chronic mainte-
nance of the early tissue repair stage and scarring. On thecontrary, it is believed that the anti-inflammatory proper-
ties of MSCs result in the eventual scar resorption (Caplan
and Correa, 2011). According to this model, distinct stromal
populations have the capacity to execute opposing functions
that operate in succession in tissue repair. In chronic pathol-
ogy, MSCs and fibrocytes might have opposing long-term
roles with MSCs being “the good” and fibrocytes being “the
bad”. However, this remains speculative until the tools to
track and inactivate each population are developed and
this hypothesis is tested experimentally. With cardiovascular
disease being a major cause of death, understanding the role
of pro-fibrotic progenitors in heart pathologies is very impor-
tant, however the progress in this field is still minimal (Khan
and Sheppard, 2006). Here, we will focus on renal and lung
fibrosis as the examples of pathologies relying on stromato-
genesis that are characterized comparatively well.
Chronic kidney disease is a debilitating condition occur-
ring with an increasing incidence of over 13% in the US pop-
ulation (Coresh et al., 2007). Renal pathology usually
initiates as a wound healing response aimed at the restora-
tion of the normal architecture, and the recovery of func-
tion. Because tissue repair in the adult does not come to
completion and is complicated by infections and inflamma-
tory conditions such as obesity and diabetes, fibrosis does
not become resolved and gradually progresses to a chronic
state and results in tubulointerstitial and glomerular fibro-
sis. The excess accumulation of scar tissue composed of
ECM molecules such as collagen leads to gradual loss of kid-
ney function. Manifestations of chronic renal fibrosis (CRF),
including glomerulosclerosis, vascular sclerosis, and tubu-
lointerstitial fibrosis are the histological predictors of the
end-stage disease (Liu, 2006). These transformations result
in irreversible kidney failure over time and eventually re-
quire dialysis or transplantation for patient survival. Tissue
and cell lineage origins of the stromal cells responsible for
CRF are unclear. Interstitial fibroblasts, glomerular mesan-
gial cells, and vascular smooth muscle cells are phenotypi-
cally similar, with the fibroblasts and mesangial cells
acquiring features of smooth muscle when activated
(Wynn, 2008). Renal EMT is proposed to be important at
later stages of kidney disease progression (Rastaldi, 2006;
Kriz et al., 2011). The relative contributions of EMT-
derived cells, MSCs, and fibrocytes to CRF remain to be de-
termined. The reported correlation between obesity and
CRF (Thakur et al., 2006; Sachse and Wolf, 2008) could be
explained by possible migration of MSCs from WAT.
Idiopathic pulmonary fibrosis (IPF) is a rapidly progressing
fatal illness with incidence of 0.03% in the U.S. population
(Gross and Hunninghake, 2001). In IPF, the results of inflam-
mation and fibrosis are evident radiographically and on biopsy
as diffuse pulmonary infiltrates. Scarring resulting from ECM
deposition is associated with alveolar epithelial cell injury,
type II cell hyperplasia, progressive loss of normal lung archi-
tecture, dyspnea, and ultimately impaired respiratory func-
tion (Keane et al., 2005). The complexity of this pneumonia
is revealed by heterogeneity of the fibrotic lesions/foci, and
unpredictable progression to acute exacerbation. As in other
fibrotic conditions, the origin of pathological stromal cells de-
positing ECM proteins is not understood. Conversion of resi-
dent fibroblasts and possibly alveolar epithelial cells through
EMT takes place in advanced stages of fibrosis (Willis et al.,
2006). However, it has become clear that differentiation of
MSC
EMT
fibrocyte
fibrotic 
  ECM
+
+ +
Figure 3 Relationship between different populations of pathological stromal cells. A working model according to which fibroblasts
derived from MSCs, fibrocytes, and through EMT, communicate in creating and maintaining the scar tissue in fibrosis. Indicated are
positive (+) and negative (−) effects on ECM deposition and function of each other.
318 M.G. Kolonin et al.circulating progenitors derived from remote organs is impor-
tant, in particular at early stages of lung disease. Interesting-
ly, obesity is associated with prolonged survival in IPF patients
(Alakhras et al., 2007), suggesting that WAT-derived factors
may have beneficiary effects. These factors could in theory
correspond to the migrating adipose MSCs and/or fibrocytes.
Interestingly, survival of lung cancer patients positively corre-
lates with obesity, while the opposite is the case for most
other types of cancer (Flegal et al., 2007).Stromal cells in cancer
Like wound healing, cancer progression relies on the recruit-
ment of stem cells and partially differentiated progenitor
cells (Dvorak, 1986). This occurs to a large extent through sys-
temic cell mobilization and attraction from remote organs, as
well as possibly via cell migration from surrounding tissues
(Laird et al., 2008). Cancer progression relies on blood vessel
formation (Folkman, 2006). Tumor neovascularization predom-
inantly occurs through adjacent resident vasculature sprouting
into the tumor (angiogenesis) in response to factors released
by the hypoxic and inflammatory tumor microenvironment
(Carmeliet and Jain, 2000). Recruitment of circulating progen-
itors into blood vessels (post-natal vasculogenesis) also plays an
important role in formation of new vessels (Bertolini et al.,
2006; Shaked et al., 2006). The numbers of circulating hemato-
poietic progenitor cells (HPC) endothelial progenitor cells
(EPC), and mature EC are elevated in cancer (Bertolini et al.,
2006; Folkman, 2006), and there is evidence for EPC recruit-
ment by human tumors (Peters et al., 2005). The implication
of distantly mobilized cells in cancer is illustrated by animal
studies demonstrating that bone marrow-derived progenitors
contribute to tumor microenvironment and promote cancer
progression (Lyden et al., 2001; Gao et al., 2008).
Despite numerous therapeutic approaches aimed at neo-
plastic and vascular cells, resistance of cancer to treatmentremains a challenge. This has led to realization that, in addi-
tion to vascular cells, stromal cells represent a key component
of the tumor microenvironment contributing to therapy resis-
tance (Fukumura et al., 1998; Bissell and Radisky, 2001; Wels
et al., 2008). In addition to the EMT phenomenon, benign res-
ident and recruited stromal cells are clearly implicated both
at early stages of cancer and in metastasis. The tumor stroma
cells are collectively termed cancer-associated fibroblasts
(Karnoub et al., 2007). It has been proposed that mesenchy-
mal progenitors, upon tumor infiltration, re-establish the tro-
phic microenvironment that they normally maintain in the
bone marrow (Wels et al., 2008). Cells of tumor stroma facili-
tate neovascularization by secreting pro-angiogenic and anti-
apoptotic factors. In addition, the ability of mesenchymal
tumor cells to suppress T cell-mediated cytotoxicity has
been proposed to account for the resistance of cancer to the
immune system (Fukumura et al., 1998; Bissell and Radisky,
2001). Activation and proliferation of cancer fibroblasts lead
to their differentiation into myofibroblasts/reactive stroma
(Coussens and Werb, 2002). The ensuing tumor fibrosis is man-
ifested by desmoplastic ECM remodeling (Dvorak, 1986).
Gene expression profiling suggests that at least a propor-
tion of tumor fibroblasts originate from MSCs (Galie et al.,
2007). This notion is also supported by the presence of
CD45-PDGFRβ+ cells in tumors (Fig. 4). Because MSCs have
been shown to function as pericytes (Crisan et al., 2008;
Tang et al., 2008; Traktuev et al., 2008), the stimulatory
effects of MSCs on cancer progression (Hall et al., 2007;
Lazennec and Jorgensen, 2008) are consistent with peri-
cytes presenting a target complimentary to endothelial
cells (Bergers et al., 2003; Lu et al., 2007; Sennino et al.,
2007). In addition to their pro-angiogenic effects, MSCs se-
crete trophic and anti-apoptotic factors and have a protec-
tive anti-immune effect on tumors (Mishra et al., 2009).
Combined, these effects may have a potent positive effect
on tumor growth, which has been demonstrated in various
models. In addition, MSCs secrete chemoattractants that
319Stroma cell progenitorsmay engage infiltration of fibrocytes and other types of leu-
kocytes, some of which synergize in promoting cancer
progression.
While accumulating evidence indicates that MSCs give
rise to tumor stroma, hematopoietic cells contribute to a
comparable extent (Du et al., 2008; Dawson et al., 2011).
Bone marrow transplantation studies in mice show that 25%
of cancer myofibroblasts, especially at the periphery of the
tumor, are derived from the bone marrow (Direkze et al.,
2004) and express CD45 (Udagawa et al., 2006) as illustrated
by our unpublished data (Fig. 4). While lymphocytes do infil-
trate tumors and affect cancer progression (DeNardo et al.,
2010), the majority of marrow-derived stromal cells are of
myeloid lineage (Shojaei et al., 2008). All independently
reported monocytic populations including tumor-associated
dendritic cells (TADC), recruited bone marrow-derived cir-
culating cells (RBCC), TIE2-expressing monocytes (TEM),
and myeloid-derived suppressor cells (MDSC) appear to pro-
mote cancer angiogenesis in a paracrine manner (Bertolini
et al., 2006; Folkman, 2006). There is also evidence that
bone marrow-derived myeloid progenitors may give rise to
a subpopulation of tumor pericytes (Kim et al., 2009).
Whether these populations and fibrocytes are truly distinct,
or if they all represent the same plastic myeloid lineage pool
collectively playing a role in the tumor stroma, remains to
be determined.
Whether MSCs, monocytic cells, and EMT-derived stroma
affect tumor progression positively or negatively may be
context-dependent, which offers an interesting subject of
investigation. There is evidence for epigenetically altered fi-
broblasts driving not only cancer progression, but also initia-
tion (Bhowmick et al., 2004), which makes the origin of
stromal progenitor cells in cancer particularly important.
We recently analyzed migration of WAT-derived cells in re-
sponse to cancer signals (Zhang et al., 2009). Our experi-
ments showed that adipose MSCs become mobilized from
WAT implants and migrate to tumors, which is associated
with accelerated tumor growth. We also showed that WAT-
derived MSCs migrate to tumors through the systemic circu-
lation upon subcutaneous administration, and engraft the
perivascular niche, which is sufficient to promote cancerFigure 4 Tumor mesenchymal and hematopoietic stromal cells. Co
carcinoma (LLC) tumors grafted into C57BL/6 mice. Shown are dif
PDGFRβ (red) and mouse CD45 (green); or (B) mouse PDGFRβ (red)
PDGFRβ+. Host hematopoietic stromal cells are CD45+ (A). Host vasc
for CD31 and PDGFRβ. Nuclei are stained blue with TO-PRO-3. Scaleprogression. We propose this phenomenon to at least partial-
ly explain the epidemiological association between obesity
and cancer (Zhang et al., 2010). Interestingly, recruitment
of ASCs, but not of marrow-derived or lung-derived MSCs,
promoted tumor growth in mice in our study (Zhang et al.,
2009), indicating that MSCs from WAT have a unique trophic
function. The cancer-promoting properties of adipose stro-
ma have been recently reported by other groups (Dirat et
al., 2011; Zimmerlin et al., 2011). Combined, the results of
these studies suggest that different organs serve as reser-
voirs of stromal precursors that may have distinct properties
and tumor-promoting capacities. While clinical trials using
stromal cells in regenerative medicine are underway, the ac-
cumulating evidence that stromal cells can promote cancer
progression indicates that caution must be used.Conclusion
A number of questions regarding the etiology of stromal fi-
broblasts remain unanswered. The relative contribution of
bone marrow, as opposed to other organs and resident tis-
sue, to the pools of pathological stromal cells is to be de-
fined in different pathological settings (Fig. 2). The
relative content of mesenchymal progenitors, monocytes,
and EMT-derived cells in pathological stroma is also yet to
be characterized in disease-specific contexts. An important
question is whether EMT-, MSC- and monocyte-derived stro-
mal cells execute complementary or opposing functions dur-
ing fibrotic pathogenesis (Fig. 3). It is unclear to which
extent trans-differentiation of plastic fibroblast progenitors
recruited into the lesion complicates the issue. Progress has
been limited by the lack of reliable markers that could dis-
tinguish the distinct populations of stromal cells. In the
past, various approaches have been undertaken to charac-
terize molecular differences between stromal populations,
however success in this endeavor has been limited. Recent
identification of a new marker of adipose MSCs (Daquinag
et al., 2011a) sets the stage for efforts toward systematic
characterization of stromal progenitor markers. In the fu-
ture, identification of differentially expressed cell surfacenfocal immunofluorescence analysis of sections from Lewis lung
ferent tumor areas stained with antibodies against (A) mouse
and mouse CD31 (green). Host mesenchymal stromal cells are
ular endothelium is CD31+ (B). Malignant LLC cells are negative
bar: 50 μM.
320 M.G. Kolonin et al.molecules may enable targeting of stromal cell populations.
Understanding the properties and roles of EMT-derived cells,
MSCs, and monocytic stroma from bone marrow and other
organs may outline strategies to differentially control the
functions of the respective cell populations in order to sup-
press disease progression. We envision therapies aimed at
specific stromal cell pools becoming a complementary treat-
ment of fibrosis and cancer. New stromal cell markers will
make it possible not only to quantify distinct populations of
pathological stromal cells in disease, but also to ablate a de-
sired subpopulation. Conversely, the approach of using MSCs
as vehicles (Hall et al., 2007) might be expanded to fibro-
cytes and EMT-derived cells for directing treatment to de-
sired sites for therapeutic purposes.Acknowledgments
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